FRAZER, Pennsylvania ( TheStreet) -- Cephalon ( CEPH) intends to make a takeover bid for ChemGenex Pharmaceuticals, the Australian biopharmaceutical company.

The total offer value for ChemGenex shares and listed ChemGenex options that Cephalon doesn't own is about $163 million, Cephalon said in a statement. The offer values all ChemGenex shares and options at about $231 million.

The takeover bid has the support of ChemGenex directors, who will recommend it to shareholders as long as a superior offer doesn't come along.

ChemGenex plans to file a new drug application with the Food and Drug Administration to sell Omapro, a treatment for chronic myeloid leukemia.

-- Written by Joseph Woelfel

>To contact the writer of this article, click here: Joseph Woelfel

>To submit a news tip, send an email to: tips@thestreet.com.

If you liked this article you might like

Tech IPO Offensive, M&A Retreat: Deals to Watch

8 Stocks Setting New 52-Week Highs

8 Stocks Setting New 52-Week Highs

TE Connectivity to Join S&P 500

TE Connectivity to Join S&P 500

Cephalon Reaches New 52-Week High (CEPH)

Cephalon Reaches New 52-Week High (CEPH)

Cephalon Reaches New 52-Week High (CEPH)

Cephalon Reaches New 52-Week High (CEPH)